Molecular Partners Stock

Molecular Partners EBIT

The EBIT of Molecular Partners (MOLN.SW) as of Aug 20, 2026 is -55.44 M CHF. In the previous year, EBIT was -61.22 M CHF — a change of -9.45% (higher).

EBIT

-55.44 MCHF

YoY

-9.45%

Last updated:

In 2026, Molecular Partners's EBIT was -55.44 M CHF, a -9.45% increase from the -61.22 M CHF EBIT recorded in the previous year.

The Molecular Partners EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M CHF)
Date
EBIT (M CHF)
Jan 1, 2023
-61.11 base
Jan 1, 2024
-61.22 base
Jan 1, 2025
-55.44 base
Jan 1, 2026 (e)
-3.05 base
Jan 1, 2027 (e)
-17.03 base
Jan 1, 2028 (e)
-0.35 base
Jan 1, 2029 (e)
-9.29 base
Jan 1, 2030 (e)
-49.63 base
YEAREBIT (M CHF)
2030 est -49.63
2029 est -9.29
2028 est -0.35
2027 est -17.03
2026 est -3.05
2025 -55.44
2024 -61.22
2023 -61.11
2022 116.61
2021 -63.33
2020 -58.33
2019 -36.66
2018 -37.41
2017 -25.84
2016 -19.49
2015 -2.22
2014 1.84
2013 7.12
Access this data via the Eulerpool API

Molecular Partners Revenue

Molecular Partners Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
7.04 M CHF
-61.11 M CHF
-61.98 M CHF
Jan 1, 2024
4.97 M CHF
-61.22 M CHF
-54.04 M CHF
Jan 1, 2025
0.00 CHF
-55.44 M CHF
-61.65 M CHF
Jan 1, 2026 (e)
11.00 M CHF
-3.05 M CHF
-48.84 M CHF
Jan 1, 2027 (e)
61.50 M CHF
-17.03 M CHF
-44.16 M CHF
Jan 1, 2028 (e)
1.25 M CHF
-346,202.00 CHF
-51.05 M CHF
Jan 1, 2029 (e)
33.55 M CHF
-9.29 M CHF
-49.35 M CHF
Jan 1, 2030 (e)
179.20 M CHF
-49.63 M CHF
3.40 M CHF

Molecular Partners Margins

Molecular Partners stock margins

The Molecular Partners margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Molecular Partners. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Molecular Partners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
-579.80 %
-868.26 %
-880.70 %
Jan 1, 2024
-855.81 %
-1,231.73 %
-1,087.38 %
Jan 1, 2025
-855.81 %
- %
- %
Jan 1, 2026 (e)
-855.81 %
-27.70 %
-443.97 %
Jan 1, 2027 (e)
-855.81 %
-27.70 %
-71.80 %
Jan 1, 2028 (e)
-855.81 %
-27.70 %
-4,083.90 %
Jan 1, 2029 (e)
-855.81 %
-27.70 %
-147.09 %
Jan 1, 2030 (e)
-855.81 %
-27.70 %
1.90 %

Molecular Partners Stock analysis

What does Molecular Partners do? Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Molecular Partners's EBIT

Molecular Partners's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Molecular Partners's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Molecular Partners's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Molecular Partners’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Molecular Partners stock

EBIT of Molecular Partners is -55.44 M CHF in 2026.

EBIT of Molecular Partners changed from -61.22 M CHF to -55.44 M CHF, representing a -9.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Molecular Partners since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Molecular Partners historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Molecular Partners

All Key Metrics — Molecular Partners